Damla Bozkulak

🔬 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐎𝐥𝐢𝐠𝐨𝐧𝐮𝐜𝐥𝐞𝐨𝐭𝐢𝐝𝐞 𝐒𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐈𝐨𝐧 𝐌𝐨𝐛𝐢𝐥𝐢𝐭𝐲–𝐌𝐚𝐬𝐬 𝐒𝐩𝐞𝐜𝐭𝐫𝐨𝐦𝐞𝐭𝐫𝐲 🧬 As therapeutic oligonucleotides continue to gain traction in the treatment of rare and chronic diseases, the need for accurate, high-throughput sequence confirmation has never been greater. Traditional LC-MS/MS approaches often require multiple injections and are limited by charge-state-specific fragmentation and low throughput. 📈 In this study, a 𝐦𝐮𝐥𝐭𝐢𝐝𝐢𝐦𝐞𝐧𝐬𝐢𝐨𝐧𝐚𝐥 𝐋𝐂-𝐈𝐌𝐒-𝐂𝐈𝐃-𝐌𝐒 platform was developed to tackle these challenges. By integrating 𝐢𝐨𝐧 𝐦𝐨𝐛𝐢𝐥𝐢𝐭𝐲 𝐬𝐩𝐞𝐜𝐭𝐫𝐨𝐦𝐞𝐭𝐫𝐲, 𝐝𝐫𝐢𝐟𝐭 𝐭𝐢𝐦𝐞–𝐝𝐞𝐩𝐞𝐧𝐝𝐞𝐧𝐭 𝐜𝐨𝐥𝐥𝐢𝐬𝐢𝐨𝐧-𝐢𝐧𝐝𝐮𝐜𝐞𝐝 𝐝𝐢𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐢𝐨𝐧, and 𝐦𝐚𝐬𝐬 𝐬𝐩𝐞𝐜𝐭𝐫𝐨𝐦𝐞𝐭𝐫𝐲, the authors enabled: ✅ Separation and analysis of multiple charge states in a single injection ✅ Application of optimized, charge-specific collision energies using drift time-dependent voltage ramps ✅ Sequence coverage up to 85% for 21-mer DNA/RNA sequences ✅ A novel data preprocessing pipeline coupling the PNNL PreProcessor with Agilent BioConfirm, enabling streamlined all-ion fragmentation data interpretation 🧪 The method was validated across diverse oligonucleotide types—including phosphorothioate-modified strands and sequences up to 40-mers—demonstrating adaptability and robustness. While sequence coverage decreased with increasing strand length, the workflow proved particularly well-suited to the therapeutic range (15–30 bases). 📊 This represents a promising direction toward 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭 𝐐𝐂 𝐰𝐨𝐫𝐤𝐟𝐥𝐨𝐰𝐬 for synthetic oligonucleotides, including those with chemically modified backbones. 🎯 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞-𝐀𝐰𝐚𝐲𝐬: • LC-IMS-CID-MS enables single-injection, multi-charge-state oligonucleotide analysis • Drift time–dependent CE ramps optimize fragmentation across species • New data workflow supports high-throughput sequence confirmation • Effective for therapeutic-length oligos, with potential to expand via other dissociation methods 🔗 𝐅𝐮𝐥𝐥 𝐩𝐚𝐩𝐞𝐫 available here (behind paywall 💰): https://lnkd.in/emMg7Wix #Oligonucleotides #MassSpectrometry #IonMobility #AnalyticalChemistry #Biopharma #NucleicAcidTherapeutics #DrugDevelopment #LCMS #Bioanalysis #PharmaceuticalScience Jack Ryan, PhD, Gordon Slysz, Peter Rye, Sarah Stow, James Dodds, John Sausen & Erin Baker

154

4 Yorum

timsMetabo™ is redefining what's possible in small molecule analysis in 4D-Metabolomics™ and 4D-Lipidomics™. 🔍 With Mobility Range Enhancement (MoRE) and the TIMS-MX analyzer, timsMetabo delivers a triple advantage: · Greater ion separation capacity to resolve isomers, isobars, and interferences—minimizing chimeric MS/MS spectra and enhancing selectivity · Improved sensitivity and MS/MS efficiency with mobility-based ion sorting · Higher annotation confidence with accurate and reproducible CCS measurements as additional molecular descriptors Explore the brochure to see how timsMetabo is redefining 4D-Metabolomics and 4D-Lipidomics workflows: https://lnkd.in/eg3gAij5 #Bruker #Metabolomics #timsMetabo #TIMS #massspectrometry

90

Pharming announces upcoming presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and insights into APDS and additional primary immunodeficiencies (PIDs) with immune dysregulation. https://bit.ly/4iwjxDy

46

We are pleased to announce the introduction of new panel - AgilusEDGE Comprehensive Genomic Profile (CGP) test for oncology diagnostics. With AgilusEDGE CGP test, oncologists can now access comprehensive genomic profiling of 500+ genes in just 4 days, a significant advancement from the earlier turnaround time (TAT) of around 30 days. With the introduction of this panel, Agilus Diagnostics becomes the first commercial laboratory in India to offer lightning-fast TAT for multi-gene profiling across solid tumors, setting a new benchmark in cancer diagnostics. Dr Anand K, Ashish Bhatia, Abhinav Kalra, Dr. Shrinidhi Nathany, Dr. Rahul Bhargava, Varun singh, Rashmi Sharma #AgilusDiagnostics #Oncology #Genomics

69

8 Yorum

🚀 Accelerating Regulatory Confidence in Microphysiological Systems (MPS) TissUse GmbH is proud to be part of a groundbreaking initiative advancing the use of liver MPS in regulatory science. Led by the The 3Rs Collaborative (3RsC), in partnership with FDA-#CDER, The National Institutes of Health-#NICEATM, and Critical Path Institute (C-Path), this first-of-its-kind project brings together regulators, MPS developers, and end-users to evaluate how liver MPS platforms can detect drug-induced liver injury (DILI)—a critical challenge in drug safety assessment. 🔬 Our HUMIMIC multi-organ MPS platform is one of nine commercial systems being tested using a unified experimental protocol and a blinded panel of hepatotoxicants. 🧠 Why this matters: This collaboration is more than a scientific study—it's a blueprint for how developers, regulators, The National Institutes of Health, and pharma can jointly shape the future of drug development using human-relevant, data-rich, and ethically aligned approaches. 📌 What we’re doing: • Testing known hepatotoxicants across multiple MPS platforms • Using real-world regulatory protocols • Analyzing cross-platform data to inform best practices • Submitting a joint Letter of Intent to FDA’s ISTAND program for context-specific MPS qualification This effort is a major step toward harmonizing innovation and regulatory science—and it's just the beginning. 🔗 Learn more about the initiative and explore the 3RsC MPS Tech Hub: www.3rc.org/mps Let’s advance the science—together. #3Rs #MPS #DILI #RegulatoryScience #Toxicology #BiomedicalInnovation #ScienceWithCompassion #FDA #NAMs #MicrophysiologicalSystems #3RsCollaborative #BetterScience

53

2 Yorum

Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form We are pleased to share this article by Rahel Wallimann, PhD, Avni Mehta, Ana Katrina Mapanao, Ulli Köster, Rainer Kneuer, Patrick SCHINDLER, Nicholas P. van der Meulen, Roger Schibli and Cristina Müller using #Mediso nanoScan® SPECT/CT system. https://lnkd.in/gGut7qs7 #imaging #preclinicalimaging #molecularimaging

87

1 Yorum

Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer https://lnkd.in/dj_Ngzb2 In a multicohort, phase 1a–1b trial, the oral HER2-selective tyrosine kinase inhibitor💊 zongertinib demonstrated promising efficacy and manageable safety in patients with previously treated HER2-mutant non–small-cell #LungCancer ( #NSCLC )🫁. Among patients with tyrosine kinase domain mutations (cohort 1) receiving 120 mg daily, 71% achieved a confirmed objective response, with a median duration of response of 14.1 months and median progression-free survival of 12.4 months. Patients previously treated with HER2-directed antibody–drug conjugates (cohort 5) had a 48% response rate, while those with non–tyrosine kinase domain mutations (cohort 3) showed a 30% response rate. High-grade drug-related adverse events were relatively infrequent, and no drug-related interstitial lung disease was observed, supporting zongertinib’s clinical potential in this population. Nicolas Girard, Egbert Smit David Planchard Byoung Chul Cho Noboru Yamamoto, Joshua Sabari Ernest Nadal Behbood Sadrolhefaazi Sabina Eigenbrod-Giese, MD, PhD, MBA Ping OncoAlert Thoracic Faculty Biagio Ricciuti Stephen Liu Hidehito Horinouchi Christine M. Lovly, MD, PhD, FASCO GILBERTO de lima LOPES Junior Jill Feldman Jarushka Naidoo

571

2 Yorum

✅AliveDx obtains CE Mark for MosaiQ AiPlex Vasculitis assay The MosaiQ AiPlex VAS assay is designed to expedite diagnosis of autoimmune vasculitis by delivering quicker results and streamlining laboratory workflows. It enhances the diagnosis through improved testing of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides and Anti-GBM (Goodpasture’s) disease. ANCA-associated vasculitides include eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). The three conditions cause blood vessel inflammation, potentially leading to severe organ damage if untreated. The CE mark allows the clinical use of MosaiQ AiPlex assay in the EU and other countries accepting the IVDR-CE mark. The MosaiQ platform offers a high-throughput, automated multiplexing capability, combining multiple markers into one test for insights and reduced hands-on time. Read more online: https://lnkd.in/gisHixRU 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter

85

3 Yorum

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Biohaven CEO Vlad Coric, M.D. talks degraders, ion channel programs, and ADCs. He describes updates given for the degrader programs targeting IgG, IgA nephropathy, and peripartum cardiomyopathy.. Plus, ion channel programs BHV-7000 and BHV-2100, and ADCs including TROP2. Full video: https://lnkd.in/gX7jjwNT BiotechTV's coverage of SF Healthcare Week is brought to you by: HSBC Innovation Banking BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

115

1 Yorum